Indivior Pharmaceuticals (INDV) Retained Earnings (2021 - 2026)

Indivior Pharmaceuticals' Retained Earnings history runs 6 years deep, the most recent figure standing at -$280.0 million for Q1 2026.

• In Q1 2026, Retained Earnings rose 31.03% year-over-year to -$280.0 million; the TTM figure through Mar 2026 stood at -$280.0 million (up 31.03% YoY), while the FY2025 annual figure was -$243.0 million, down 575.0% from the prior year.
• Retained Earnings was -$280.0 million for Q1 2026 at Indivior Pharmaceuticals, down from -$243.0 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $1.3 billion in Q4 2022 to a low of -$406.0 million in Q1 2025.
• Historically, Retained Earnings has averaged -$41.1 million across 5 years, with a median of -$261.5 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings soared 200.62% in 2022, then sank 575.0% in 2025.
• A 5-year view of Retained Earnings shows it stood at $1.3 billion in 2022, then sank by 122.1% to -$288.0 million in 2023, then soared by 87.5% to -$36.0 million in 2024, then tumbled by 575.0% to -$243.0 million in 2025, then retreated by 15.23% to -$280.0 million in 2026.
• The last three Retained Earnings figures came in at -$280.0 million (Q1 2026), -$243.0 million (Q4 2025), and -$346.0 million (Q3 2025), per Business Quant data.